4 documents found, page 1 of 1
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing...
Georgiadis, Stylianos; Ørnbjerg, Lykke Midtbøll; Michelsen, Brigitte; Kvien, Tore K.; Giuseppe, Daniela Di; Wallman, Johan K.; Závada, JakubFunding Information: On behalf of the EuroSpA Scientific Committee, the authors acknowledge Novartis Pharma AG and IQVIA for supporting the EuroSpA Research Collaboration Network. Publisher Copyright: © 2024 The Journal of Rheumatology.; Objective. Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) t...
Impact of patient characteristics on ASDAS disease activity state cut-offs in a...
Ørnbjerg, Lykke M.; Georgiadis, Stylianos; Kvien, Tore K.; Michelsen, Brigitte; Rasmussen, Simon; Pavelka, Karel; Zavada, Jakub; Loft, Anne GittePublisher Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.; OBJECTIVES: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a la...
Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthr...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiThe authors regret that the following incorrect values have been published in the original paper: In the abstract: Line 11-12: “age, per year: 0.97 (0.97-0.98)” should be “age, per year: 0.98 (0.97-0.99)” Line 12: “men vs. women: 1.88 (1.60-2.22)” should be “men vs. women: 1.79 (1.51-2.12)” Line 12: “current vs. non-smoking: 0.76 (0.63-0.91)” should be “current vs. non-smoking: 0.72 (0.59-0.87)” Line 12-13: “HL...
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during trea...
Ørnbjerg, Lykke M.; Linde, Louise; Georgiadis, Stylianos; Rasmussen, Simon H.; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Giuseppe, Daniela DiFunding Information: LMØ, LL, SG and SHR: research grants from Novartis; UL: none; DDG none; JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly and Novartis; BG: research grants from Pfizer, Abbvie and BMS; LP: consultant of Novartis Finland, UCB Pharma, Pfizer, Sanofi, BMS, AbbVie, Amgen, Celgene, Eli Lilly, Boehringer-Ingelheim, Mylan; KL: consulting and/or speaking fees from Amgen, Johnson and Johnson and ...